Person: SALMAN, ANDAÇ
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SALMAN
First Name
ANDAÇ
Name
27 results
Search Results
Now showing 1 - 10 of 27
Publication Metadata only Effectiveness of Omalizumab in Patients with Chronic Inducible Urticaria: real-life experience from two UCARE centres(2021) SALMAN, ANDAÇ; Can, P. K.; Salman, A.; Hoşgören-Tekin, S.; Kocatürk, E.Publication Metadata only What determines the treatment persistence in paediatric psoriasis?(WILEY, 2021) SALMAN, ANDAÇ; Salman, A.Publication Metadata only Autoimmune progesterone dermatitis mimicking fixed drug eruption(2017) SALMAN, ANDAÇ; Salman, Andac; Ergun, TulinPublication Metadata only Remission of chronic spontaneous urticaria following omalizumab with gradually extended dosing intervals: Real-life data(WILEY, 2021) SALMAN, ANDAÇ; Salman, Andac; Aktas, Meryem; Sengun, Ozlem AptiOmalizumab is a well-established treatment option in chronic spontaneous urticaria unresponsive to antihistamines at standard or higher doses. However, characteristics of the remission and relapse following the withdrawal of omalizumab remain largely unknown. We aimed to define the characteristics of remission in CSU following omalizumab with gradually lengthened dosing intervals in this retrospective study of 102 patients who were treated with at least 5 doses of omalizumab between 2015 and 2020. Of 102 patients, 70 (68.6%) showed a CR to omalizumab at standard doses. Omalizumab could be discontinued in 47 of 70 patients using gradually lengthened dosing intervals. Following a mean follow-up duration of 12.2 months, 25 (58.1%) patients were still in remission while 18 (41.9%) had relapse (Follow-up data were not available in 4 patients). The relapses were unresponsive to antihistamines in 14 patients (77.7%), however, retreatment with omalizumab led to complete control of symptoms. The patients younger than 40 were more likely to relapse. Despite the need for comparison with fixed-dosing intervals in larger, prospective studies, the results of this study imply that omalizumab with gradually extended dosing intervals might provide a long duration of remission in CSU.Publication Metadata only Acute generalized exanthematous pustulosis due to ceftriaxone: Report of a pediatric case with recurrence after positive patch test(WILEY, 2019) SALMAN, ANDAÇ; Salman, Andac; Yucelten, Deniz; Cakici, Ozlem Akin; Kadayifci, Eda KepenekliAcute generalized exanthematous pustulosis (AGEP) is seen uncommonly in children and sometimes shows atypical clinical features in this population. Patch testing can be used effectively in children for the confirmation of the culprit drug in cases of multiple drug use. Here, we report a rare, pediatric case of ceftriaxone-induced AGEP confirmed by patch testing with subsequent recurrence of the skin eruption.Publication Metadata only Expanding the differential diagnosis of raccoon eyes: sweet syndrome(2019) SALMAN, ANDAÇ; Salman, A.; Demir, G.; Cinel, L.; Oguzsoy, T.; Yıldızhan, G.; Ergun, T.Publication Metadata only Slime: A trending cause of isothiazolinone contact allergy in children(WILEY, 2019) SALMAN, ANDAÇ; Salman, Andac; Demir, Gizem; Apti, OzlemPublication Metadata only Concurrence of immune thrombocytopenic purpura and alopecia areata: A rare association(Medknow Publications, 2016) SALMAN, ANDAÇ; Salman A., Eser A.[No abstract available]Publication Metadata only Methylchloroisothiazolinone and methylisothiazolinone contact allergy: A retrospective cohort study from a tertiary dermatology clinic in Turkey(WILEY, 2019) SALMAN, ANDAÇ; Salman, AndacPublication Metadata only Acquired progressive lymphangioma: Case report with partial response to imiquimod 5% cream(WILEY, 2017) SALMAN, ANDAÇ; Salman, Andac; Sarac, Gonca; Kuru, Burce Can; Cinel, Leyla; Yucelten, Ayse Deniz; Ergun, TulinAcquired progressive lymphangioma (APL), or benign lymphangioendothelioma, is an unusual entity derived from vascular structures. Clinically and histopathologically it may resemble Kaposi's sarcoma and well-differentiated angiosarcoma, causing a diagnostic problem. We report an individual with APL initially diagnosed with Kaposi's sarcoma who underwent unnecessary laboratory testing. Imiquimod 5% cream stopped the progression of the lesion. Awareness of this rare entity may prevent patients from undergoing excessive testing. Imiquimod may be used as a safe, effective treatment option.
- «
- 1 (current)
- 2
- 3
- »